GlassScriptPhysician profile
Joshua E Hansen
NPI 1588948087
$7,819.96
in general payments reported to CMS, 2019-2025
55 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,519 · 2022: $1,804 · 2023: $1,439 · 2024: $1,450 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,509.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $600.89 | 2021-2025 | Rexulti |
| Amgen INC. | $546.80 | 2021-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $535.95 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $242.88 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $234.87 | 2021-2025 | |
| Grifols USA, LLC | $229.17 | 2021-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $226.87 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $217.54 | 2021-2024 | Farxiga, Flumist Quadrivalent, Breztri |
| Sanofi-Aventis U.S. LLC | $213.98 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $203.01 | 2022-2025 | Zenpep, Vowst |
| Novartis Pharmaceuticals Corporation | $199.07 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.46 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $155.96 | 2024-2025 | Voquezna |
| Lundbeck LLC | $150.72 | 2023-2025 | Rexulti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.